Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals — Investor Presentation (January 2010)

36 slides from Synergy Pharmaceuticals's investor presentation, Jan 8, 2010

  1. Slide 1: Developing new treatments for GI Disorders and Diseases

    Developing new treatments for GI Disorders and Diseases January 2010 Corporate Presentation

  2. Slide 2: Forward-Looking Information

    Certain statements made in this presentation are forward-looking. Such statements are indicated by words such as “expect,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Synergy believes that the expectations reflected in such forward-looking statement

  3. Slide 3: Introduction to Synergy Pharmaceuticals – Key Points

    Introduction to Synergy Pharmaceuticals Synergy Pharmaceuticals – Key Points Technology Proprietary technology, not in-licensed Major implications to treat GI disorders Platform potential Strong IP position Application SP-304 to treat chronic constipation and IBS-C SP-333 to treat IBD Advantages Hum

  4. Slide 4: GI Disorders & Diseases Significant Market Opportunity

    GI Disorders & Diseases Significant Market Opportunity

  5. Slide 5: Significant Unmet Medical Need

    Significant Unmet Medical Need Hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel movements per week Significantly affects patients’ quality of life by impairing their ability to work and participate in typical daily activities Limite

  6. Slide 6: The Market for GI-Disorder Drug

    The Market for GI-Disorder Drug World: 100 M people with chronic constipation and IBS-C Wide prevalence: Up to 15% and 20% of the population respectively Severe: 20 M people in US, Europe and Japan 7.5 M US 7.5 M Europe 5.0 M Japan $27 Billion total market size More than 1 Million patients More than

  7. Slide 7: Major Game-Changing Event: Novartis Zelnorm withdrawn

    Major “Game–Changing” Event: Novartis Zelnorm® (tegaserod) 5-HT4 agonist withdrawn from market in spring 2007 due to cardio-toxicity $560 M sales in 2006, worldwide 32% growth, year on year Approved for chronic constipation and IBS-C Major impact on all future 5-HT4 agonist candidates Highlights nee

  8. Slide 8: Competitive landscape – few approved products to fill Zelnorm absence

    Competitive landscape – few approved products to fill Zelnorm absence Amitiza® Amitiza® (lubiprostone) from Sucampo/Takeda Chloride C-2 channel activator Absorbed compound Main side effect is nausea - to 30% of patients Sets high price for market ~$3.80 / day retail ~$3.35 / day ex-factory

  9. Slide 9: GC-C receptor agonists

    GC-C receptor agonists

  10. Slide 10: Guanylate Cyclase C Receptors - Physiological mechanism

    Guanylate Cyclase C Receptors - Physiological mechanism Guanylate Cyclase C (GC-C) receptors are present on luminal side of gut Key regulator of salt and liquid content of gut The CFTR when activated secretes Cl- and HCO3- into intestinal lumen, along with fluid Side view of the GI tract

  11. Slide 11: Activation of chloride channels increases fluid secretion into GI lumen

    Activation of chloride channels increases fluid secretion into GI lumen Amitiza® SP-304 Linaclotide

  12. Slide 12: Big Pharma technology: History of our GC-C receptor agonists

    Big Pharma technology: History of our GC-C receptor agonists Technology emanates from cutting edge research on GCC receptors at GD Searle / Monsanto. Key researcher in field: Dr. Kunwar Shailubhai (joined Synergy Pharmaceuticals in 2000) Researchers from Monsanto/Searle eventually joined two biotech

  13. Slide 13: SP-304 lead drug: GC-C Receptor Agonist

    SP-304 lead drug: GC-C Receptor Agonist 16-mer analog of uroguanylin Single key amino acid change Locked into stable active conformer Compact stable molecule Thermo and acid stable (100 °C, pH 2) High resistance to proteases Behaves like a small molecule drug More potent than the natural hormone NDD

  14. Slide 14: Two GC-C Receptor Agonists Currently Being Developed

    ST-peptide Produced by E. coli bacteria Uroguanylin Natural Hormone Linaclotide ST-peptide Analog NDECELCVNVACTGCL SP-304 Uroguanylin Analog Two GC-C Receptor Agonists Currently Being Developed for Chronic Constipation and IBS NSSNSSNYCCELCCNPACTGCY CCEYCCNPACTGCY NDDCELCVNVACTGCL Colored lines deno

  15. Slide 15: SP-304 Phase I Trial in Volunteers

    Conclusions from study No SP-304 systemic absorption observed – all administered doses PK collected through 48 hours post-dose SP-304 showed pharmacodynamic effects indicative of drug effect Phase I Trial in Volunteers Protocol No. SP-SP304101-08 “Single-site, Randomized, Double-blind, Placebo-Contr

  16. Slide 16: Adverse Event (AE) Profile

    Adverse Event (AE) Profile The following grade 1 AEs were reported: Diarrhea (20.7%) - defined as increase in # of BM from baseline 81.8% occurred at doses of < 5.4 mg Abdominal Discomfort (5.6%) All 3 occurred at 24.3 mg dose Headache (3.7%) 1 occurred at 0.9 mg and 1 occurred at 24.3 mg dose Nause

  17. Slide 17: Study Summary

    Study Summary No systemic absorption of SP-304 observed at all administered doses PK collected through 48 hours post-dose SP-304 was well-tolerated Did not reach an MTD No serious adverse events reported Minimal AEs reported

  18. Slide 18: Next three clinical trials planned for SP-304 in CIC and IBS-C

    Next three clinical trials planned for SP-304 in CIC and IBS-C Phase 2a 14-day repeated-dose, placebo-controlled dose escalation trial in CIC patients (N~ 60) Note: linaclotide gave favorable data in 14-day Phase IIa repeated-dose study in CIC Phase 2b 28-day dose-ranging, placebo-controlled trial i

  19. Slide 19: SP-304 Clinical Development Timeline

    SP-304 Clinical Development Timeline SP-304 manufacture scale-up underway SP-304 formulation presently underway Initiate Phase 2a 14-day CC trial Initiate Phase 2b 28-day, fixed dose 28-day CC clinical trial Expect clinical data to be available to set doses for 28-day trial IND Amendment filed Janua

  20. Slide 20: Synergy's SP-304 Clinical Strategic Focus

    Synergy’s SP-304 Clinical Strategic Focus Focus clinical development of SP-304 to beat linaclotide with lower diarrhea adverse events (AE’s) Mechanistic advantage of SP-304 over linaclotide – pH dependency to binding constant Seek labeling and marketing advantages with SP-304

  21. Slide 21: SP-304 Rationale for 'Best-in-Class'

    SP-304 Rationale for ‘Best-in-Class’

  22. Slide 22: Structural Motifs of GC-C Receptor Agonists Currently Being Developed

    Structural Motifs of GC-C Receptor Agonists Currently Being Developed Modulates binding constant with mucosal acidity Colored lines denote disulphide bonds Linaclotide ST-peptide Analog NDECELCVNVACTGCL SP-304 Uroguanylin Analog CCEYCCNPACTGCY Defines agonist activity Defines agonist activity

  23. Slide 23: Physiological Role of N Terminus of Uroguanylin

    Physiological Role of N Terminus of Uroguanylin Physiological activity of uroguanylin is regulated by mucosal acidity Mucosal acidity provides physiological ‘ON’ and ‘OFF’ switch for binding of uroguanylin to GC-C First three amino acids at N-terminus (NDD) are critical for pH-mediated binding of ur

  24. Slide 24: N-terminal Amino Acids are Critical for pH-mediated Regulation

    N-terminal Amino Acids are Critical for pH-mediated Regulation of Physiological Activity Hamra et al., PNAS 1997 NDD at the N-terminus of uroguanylin (UG) - and NDE of SP-304 - are crucial for the physiological ‘ON’ and ‘OFF’ mechanism for binding to GC-C Minus NDD UG Minus NDD UG N D D C E L C V N

  25. Slide 25: Key Intellectual Property

    Key Intellectual Property Patent No. US 7,041,786 Date of Patent May 9, 2006 Title Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis Inventors K. Shailubhai, G. Nikiforovich, G. Jacob Assignee Synergy/Callisto Pharmaceuticals, Inc. Related US Appl. Data

  26. Slide 26: Platform Technology SP-333

    Platform Technology SP-333

  27. Slide 27: GC-C Receptor Agonist Program is a Technology Platform

    Synergy’s GC-C Receptor Agonist Program is a Technology Platform “Second-generation” drug positioned for ulcerative colitis (UC) IND planned for 3Q2010 First trial in healthy volunteers to test for systemic absorption IP status – Key comp-of-matter patent application published in Dec. 2008 SP-333 to

  28. Slide 28: Activation of GC-C receptor leads to GI anti-inflammatory activity

    Activation of GC-C receptor leads to GI anti-inflammatory activity cAMP AMP PKA PDE-III GTP PKG-II cGMP Na+ Ca+ Na+ Ca+ Cl- HCO3- HCO3- Cl- ClC2 CFTR CNG GC-C SP-304 SP-333 Anti-proliferative Anti-inflammatory Cl- HCO3- Na+/K+ homeostasis Amitiza® CIC & IBS IBD CANCER Intestinal lumen Epithelial mem

  29. Slide 29: Efficacy of SP-304 in Animal Models of Ulcerative Colitis

    Efficacy of SP-304 in Animal Models of Ulcerative Colitis [SP-333 studies in progress] Efficacy of SP-304 has been validated in three different acute animal models of ulcerative colitis TNBS-induced colitis in Balb/c mouse TNBS-induced colitis in BDF1 mouse DSS-induced colitis in BDF1 mouse Prelimin

  30. Slide 30: TNBS Injected Balb/c mice Treated with SP-304

    TNBS Injected Balb/c mice Treated with SP-304 show histological improvement and suppressed intestinal secretion of pro-inflammatory cytokines 0 40 80 120 IL-12 p40 IL-23 TNF Cytokines, pg/ml Control SP304, 50 mg/day 160 0 5 10 15 20 25 Histopathology Score SP-304 (mg/day) 0 10 20 50 n-9 n-8 n-4 n-5

  31. Slide 31: Initial clinical trial planned for SP-333

    Initial clinical trial planned for SP-333 Phase I single-dose, dose-escalation trial in healthy volunteers (N = 40) Safety, tolerability and PK of orally administered SP-333 Establish that SP-333 is not systemically absorbed in volunteers To be followed by evaluation in ulcerative colitis patients

  32. Slide 32: Summary

    Summary

  33. Slide 33: GC-C receptor agonists have an established valuation

    GC-C receptor agonists have an established valuation Partnership deal announced between Ironwood and Forest Laboratories for North American rights to linaclotide Forest paid $70 M upfront and $260 M in near term milestones for 50/50 rights to US, plus Canada and Mexico September 2007 May 2009 Almira

  34. Slide 34: Future Synergy Value Creation Milestones

    Future Synergy Value Creation Milestones 1Q2010 * Initiate SP-304 Phase 2a 14-day CC trial 4Q2010 * Phase 2a clinical data 2010 * File IND on SP-333 (FIH clinical data – 1Q 2011) 1Q2011 Initiate SP-304 Phase 2b 28-day CC trial 2Q2011 Initiate SP-304 Phase 2b 90-day IBS-C trial * Key 2010 Future Valu

  35. Slide 35: Synergy: Our Opportunity

    Synergy: Our Opportunity SP-304 is less than 9 months away from completing Phase IIa proof of efficacy trial in chronic constipation Oral drugs for GI disorders & diseases Targeted therapy – specific selective receptor in GI tract No systemic absorption – low risk of toxicity Clinical proof-of-princ

  36. Slide 36: Synergy Pharmaceuticals – Thank You

    Synergy Pharmaceuticals THANK YOU

Synergy Pharmaceuticals — Investor Presentation (January 2010) on 6ix